Drug profile · INN
ocrelizumab and hyaluronidase-ocsq
OCREVUS ZUNOVO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
ocrelizumab and hyaluronidase-ocsq (OCREVUS ZUNOVO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN ocrelizumab and hyaluronidase-ocsq
Brand OCREVUS ZUNOVO
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is ocrelizumab and hyaluronidase-ocsq?
ocrelizumab and hyaluronidase-ocsq (OCREVUS ZUNOVO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ocrelizumab and hyaluronidase-ocsq?
OCREVUS ZUNOVO is a marketed brand name for ocrelizumab and hyaluronidase-ocsq. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ocrelizumab and hyaluronidase-ocsq?
ocrelizumab and hyaluronidase-ocsq has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.